OncoMatch/Clinical Trials/NCT06064097
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Is NCT06064097 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Cisplatin for stage ii nasopharyngeal carcinoma ajcc v8.
Treatment: Cisplatin · Gemcitabine · Nivolumab — This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage II, III, IV
Prior therapy
Cannot have received: radiotherapy
Patients who received prior radiotherapy to the head or neck
Cannot have received: chemotherapy or radiation
Exception: for the treatment of any cancer in the last 3 years. These patients must also be in remission
Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission
Lab requirements
Blood counts
ANC ≥ 1000/uL; Platelet count ≥ 100,000/uL (transfusion independent)
Kidney function
Creatinine clearance or GFR ≥ 60 mL/min/1.73 m^2; serum creatinine based on age/sex
Liver function
Total bilirubin ≤ 1.5 x ULN for age; SGPT (ALT) ≤ 135 U/L (ULN set to 45 U/L)
Cardiac function
Shortening fraction of ≥ 27% by echocardiogram, or ejection fraction of ≥ 50% by radionuclide angiogram; no evidence of dyspnea at rest, no exercise intolerance, and pulse oximetry > 94% if indicated
Peripheral absolute neutrophil count (ANC) ≥ 1000/uL; Platelet count ≥ 100,000/uL (transfusion independent); Creatinine clearance or GFR ≥ 60 mL/min/1.73 m^2; serum creatinine based on age/sex; Total bilirubin ≤ 1.5 x ULN for age; SGPT (ALT) ≤ 135 U/L (ULN set to 45 U/L); Shortening fraction of ≥ 27% by echocardiogram, or ejection fraction of ≥ 50% by radionuclide angiogram; no evidence of dyspnea at rest, no exercise intolerance, and pulse oximetry > 94% if indicated
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Alabama · Birmingham, Alabama
- Phoenix Childrens Hospital · Phoenix, Arizona
- Arkansas Children's Hospital · Little Rock, Arkansas
- Kaiser Permanente Downey Medical Center · Downey, California
- Loma Linda University Medical Center · Loma Linda, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify